Applied Therapeutics Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Applied Therapeutics Inc. (NASDAQ:APLT) has received a consensus rating of "Moderate Buy" from six research firms, with an average twelve-month target price of $6.10.
• Institutional investors currently hold 98.31% of the company's stock, with notable new positions purchased by firms such as Ground Swell Capital LLC and Toronto Dominion Bank during the 4th quarter.
• Applied Therapeutics reported a quarterly earnings per share (EPS) of ($0.15), exceeding the consensus estimate by $0.02, and analysts project a full-year EPS of -0.65.

Shares of Applied Therapeutics Inc. (NASDAQ:APLT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $6.10.

Several equities research analysts have recently weighed in on APLT shares. Royal Bank Of Canada reissued a "sector perform" rating and issued a $1.50 target price on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC purchased a new position in Applied Therapeutics in the 4th quarter worth about $27,000. Toronto Dominion Bank bought a new position in Applied Therapeutics during the 4th quarter worth about $27,000. CreativeOne Wealth LLC grew its holdings in Applied Therapeutics by 132.2% during the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock worth $25,000 after acquiring an additional 28,701 shares in the last quarter. Dark Forest Capital Management LP grew its holdings in Applied Therapeutics by 54.5% during the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock worth $46,000 after acquiring an additional 18,949 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in Applied Therapeutics during the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Stock Up 2.9%

APLT stock opened at $0.5141 on Friday. Applied Therapeutics has a 52 week low of $0.2950 and a 52 week high of $10.6237. The company has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.44. The firm has a market capitalization of $74.04 million, a P/E ratio of -1.14 and a beta of 1.97.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. As a group, analysts anticipate that Applied Therapeutics will post -0.65 EPS for the current year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.